nach oben

Erschienen in:

15.03.2020 | Harnblasenkarzinom | Fortbildung

Harnblasenkarzinom

Die Grenzen der Zystektomie

verfasst von: Prof. Dr. med. Dr. h.c. Arnulf Stenzl, Kathrin Meisterhofer, Prof. Dr. med. Arnulf Stenzl

Erschienen in: Uro-News | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Auszug

Die radikale Zystektomie ist die Standardtherapie des muskelinvasiven Harnblasenkarzinoms und in Einzelfällen eine therapeutische Option beim nicht muskelinvasiven Harnblasenkarzinom. In diesem Artikel werden die Grenzen der Zystektomie diskutiert und die aktuellen Daten und Empfehlungen zu alternativen Therapien zusammengefasst. …

Babjuk M et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017; 71: 447-61

Gakis G et al. Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy. World J Urol. 2015; 33: 1429-37 CrossRef

Grossman HB et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol. 2012; 188: 58-62CrossRef

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 1.1, 2016, AWMF-Registrierungsnummer 03 2/038OL, http://leitlinienprogramm-onkologie.de/Harnblasenkarzinom.92.0.html; abgerufen am 6.2.2020

Sylvester RJ et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49: 466-5CrossRef

Veeratterapillay R et al. High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage. Curr Urol Rep. 2016; 17: 68

Klaassen Z. ASCO GU 2019: Keynote 057: Phase II trial of Pembrolizumab for Patients with High-risk NMIBC Unresponsive to BCG: Updated Interim Results. www.urotoday.com/conference-highlights/asco-gu-2019/asco-gu-2019-bladder-cancer/110283-asco-gu-2019-keynote-057-phase-ii-trial-of-pembrolizumab-for-patients-with-high-risk-nmibc-unresponsive-to-bcg-updated-interim-results.html; abgerufen am 6.2.2020

Alfred Witjes J et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2017; 71: 462-75

Kamat AM et al. Keynote-676: Phase 3 study of bacillus calmette-guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction. J Clin Oncol. 2019; 37: 7_suppl, TPS502-TPS502

10.

Roupret M et al. ALBAN: An open label, randomized, phase III trial, evaluating efficacy ofatezolizumab in addition to one year BCG (bacillus Calmette-Guerin) bladder instillation in BCG-naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37). J Clin Oncol. 2019; 37: 15_suppl, TPS4589-TPS4589

11.

Bernstein A. SUO 2019: The SUO-CTC Phase III Adstiladrin® Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer. https://www.urotoday.com/conference-highlights/suo-2019/suo-2019-bladder-cancer/117556-suo-2019-the-suo-ctc-phase-iii-adsiladrin-trial-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer.html; abgerufen am 6.2.2020

12.

Kramer MW et al. En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World J Urol. 2015; 33: 1937-43CrossRef

13.

Leow JJ et al. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World J Urol. 2019; 37: 61-83

14.

Gandaglia G et al. Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. Can Urol Assoc J. 2014; 8: E681-7CrossRef

15.

Donat SM et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2009; 55: 177-85

16.

Shabsigh A et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009; 55: 164-74

17.

Kim YJ et al. Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis. Oncotarget, 2017; 8: 68996-9004

18.

Schulz GB et al. Surgical High-risk Patients With ASA ≥ 3 Undergoing Radical Cystectomy: Morbidity, Mortality, and Predictors for Major Complications in a High-volume Tertiary Center. Clin Genitourin Cancer. 2018; 16: e1141-9CrossRef

19.

Young MJ et al. Radical cystectomy in the elderly - Is this a safe treatment option? Arab J Urol. 2017; 15: 360-5CrossRef

20.

De Groote R et al. Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians. J Endourol. 2016; 30: 792-8

21.

Bochner BH et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol. 2018; https://doi.org/10.1016/j.eururo.2018. 04.030

22.

Parekh DJ et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018; 391: 2525-36

23.

Schwentner C et.al. Robot-assisted radical cystectomy and intracorporeal neobladder formation: on the way to a standardized procedure. World J Surg Oncol. 2015; 13: 3CrossRef

24.

Gakis G et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013; 63: 45-57

25.

Chen RC et al. Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw. 2013; 11: 952-60CrossRef

26.

Sweeney P et al. Partial cystectomy. Urol Clin North Am. 1992; 19: 701-11

27.

Smith ZL et al. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int. 2013; 112: 13-25CrossRef

28.

Hara T et al. Primary cT2 bladder cancer: a good candidate for radiotherapy combined with cisplatin for bladder preservation. Jpn J Clin Oncol. 2011; 41: 902-7CrossRef

29.

Coen JJ et al. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2013; 86: 311-6CrossRef

30.

Rodel C et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20: 3061-71CrossRef

31.

Shipley WU et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002; 60: 62-7CrossRef

32.

Efstathiou JA et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012; 61: 705-11

33.

Gray PJ et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol. 2013; 63: 823-9

34.

Fedeli U et al. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol. 2001; 185: 72-8CrossRef

35.

Resnick MI et al. Segmental resection for carcinoma of the bladder: review of 102 patients. J Urol. 1973; 109: 1007-10CrossRef

36.

Novick AC et al. Partial cystectomy in the treatment of primary and secondary carcinoma of the bladder. J Urol. 1976; 116: 570-4CrossRef

37.

Schoborg TW et al. Carcinoma of the bladder treated by segmental resection. J Urol. 1979; 122: 473-5CrossRef

38.

Holzbeierlein JM et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol. 2004; 172: 878-81CrossRef

39.

Kassouf W et al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol. 2006; 175: 2058-62CrossRef

40.

Knoedler JJ et al. Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol. 2012; 188: 1115-9CrossRef

41.

Koga F et al. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU Int. 2012; 109: 860-6CrossRef

Titel: Harnblasenkarzinom
Die Grenzen der Zystektomie
verfasst von: Prof. Dr. med. Dr. h.c. Arnulf Stenzl
Kathrin Meisterhofer
Prof. Dr. med. Arnulf Stenzl
Publikationsdatum: 15.03.2020
Verlag: Springer Medizin
Schlagwörter: Harnblasenkarzinom
Harnblasenkarzinom
Instillationstherapie
Zystektomie
Erschienen in: Uro-News / Ausgabe 3/2020
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI: https://doi.org/10.1007/s00092-020-4075-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Die Grenzen der Zystektomie

Auszug

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Offene Op. versus DaVinci – ist der Zugangsweg entscheidend?

Hyperglykämie steigert das Nierensteinrisiko

Nierenstruktur ursächlich für Organabstoßung?

Androgendeprivation plus -rezeptorblocker: Kombitherapie beim mCSPC erfolgreich

Aufruf zum Widerspruch

Kritische Bestandsaufnahme zur fokalen Therapie

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie